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When animals are inoculated with lymphohematopoietic cells of homologous origin 
which, for one reason or another, they are unable to reject, they may be stricken with 
an often fatal, wasting syndrome, usually referred to as runt, transplantation, or homo- 
logous disease (1-3).  The essential features of this syndrome include loss of weight or 
retardation of growth, diarrhea, a diffuse dermatitis, hypertrophy of lymphoid organs 
followed by atrophy of these organs, atrophy of the thymus, and dyscrasia of the blood 
and bone marrow (4, 5). Although extensive analyses of this syndrome in rodents and 
chickens have shown that it is caused by an immunologic response on the part of the 
donor's immunologicaUy competent cells against alien transplantation  antigens of the 
host  (i.e.,  it is a  graft-versus-host [GVI-I] reaction),  its pathogenesis is still very in- 
completely understood.  The possible ancillary role of microbial organisms of endog- 
enous or exogenous origin in the immunologically debilitated hosts is still undecided. 
A  necessary condition for the development of GVH disease is incompatibility be- 
tween donor and host at the major histocompatibility locus for the species concerned 
(e.g.,  the H-2 locus in mice or the Ag-B locus in rats)  (3), and its severity depends 
principally upon the number of small lymphocytes present in the cellular inoeulum, 
thymocytes being relatively innocuous (6). 
Although,  initially,  homologous disease was regarded  as a  laboratory  artifact,  its 
occasional occurrence in man is now recognized as a consequence of either (a) a natural 
maternal ~  fetal  transplacental  "transfusion"  (7),  (b)  a  therapeutic  lymphocyte- 
containing cellular transfusion of fetuses or infants (8, 9), or (c) transplantation of bone 
marrow in the treatment of hematopoietic failure and leukemia (10). Thus, apart from 
any possible light they may shed upon the pathogenesis of homologous disease, studies 
on its prevention or arrest have clinical relevance. 
In mice, the course of runt or homologous disease can be altered by administration, 
just before or soon after injection  of the initiating homologous cellular inoculum, of a 
variety of agents including:  (a)  suspensions of isologous lymphoid cells from normal 
adult  donors;  (b)  lymphoid  cells  or  antiserum  from  isologons  donors  specifically 
sensitized against tissues of the putative attacking cells; (¢) isoantiserum specifically 
directed  against the antigens  of the host under  attack and  raised  in animals of the 
homologous strain providing the attacking  cells; and  (d)  immunosuppressive agents 
(11-17). 
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Although the pathology of runt disease has been more thoroughly studied in 
rats than in mice, few therapeutic studies have been performed in the former 
species. This is unfortunate since in infant mice the clinical  indications of certain 
bacterial and viral infections simulate those of runt disease so closely as to com- 
plicate interpretation of the results of studies designed to prevent this disease 
(3). With rats, on the other hand, the highly pathognomonic status of the skin 
lesions associated with runt disease in certain strain combinations obviates this 
complication. The purpose of this communication is to present the results of a 
comparative study of the capacity of injections of normal and sensitized isolo- 
gnus adult lymph node cells, on the one hand, and of isoantisera and heterolo- 
gous rabbit anti-rat lymphocyte serum, on the other hand, to prevent the de- 
velopment of, or abort, an acute attack of runt disease in this species. 
Materials and Methods 
Rats.-- Domestically maintained Lewis (Ag-B  1) mad BN  (Ag-B  3) isogenic strains provided 
donors mid recipients respectively. Previous work had shown that intravenous inoculation of 
neonatal BN hosts with 10-20 million lymph node cells from normal adult Lewis donors 
causes acute runt disease that is invariably fatal within 20 days (4). The first indication of 
the disease is thickening and tightness of the skin on about the 10th day, frequently  as- 
sociated with erythrodermia  of the extremities. This is rapidly  followed by a generalized 
exfoliative dermatitis, progressive increase in rigidity of the integument to the point of con- 
siderable immobilization of the limbs, arrest of weight gain, and hypothermia. 
The Disease-Inciting Inoculum.--A suspension of 20 X  106 Lewis lymph node cells, pre- 
pared  from the axillary, brachial, cervical, and mesenteric nodes, and dispensed in Hanks' 
balanced salt solution according to standard procedures described elsewhere (18) was employed 
as the standard, disease-inciting inoculum in this study. This was administered intravenously 
in a standard volume of 0.1 ml to hosts less than 24 hr old. Since this treatment causes 100% 
mortality,  the effectiveness of  the therapeutic  agents  injected  in conjunction with,  or  at 
various times before or after the "attacking" cells, was assayed in terms of their ability to 
save or prolong the subjects'  lives. 
Therapeutic Inocula.-- 
(a) Lymph node cell suspensions were prepared from normal adult BN rats,  or from BN 
rats sensitized by initial  bilateral  homografts of Lewis sldn foliowed  by a booster intraperitoneal 
injection of 200-400 X  106 Lewis lymph node and spleen cells. 
(b) Isoantisera were obtained from BN or DA rats given a primary Lewis skin graft  on 
their  right thoracic wall followed, about 10 days later,  by a similar graft  contralaterally. 
These animals subsequently received a booster intraperitoneal inoculation of Lewis lymphoid 
ceils 7 days before bleeding for serum. 
(c) Heterologous anti-lymphocyte serum (ALS) was raised by injecting adult New Zealand 
rabbits intravenously with thymic cells prepared from DA female weanling rats,  according 
to the procedure of Levey and Medawar (19, 20). After decomplementation, the serum was 
absorbed  with  rat  e2ythrocytes,  sterilized  by  filtration,  and  stored  in the deep freeze. 
The hemagglutinin titer of this antiserum against rat erythrocytes was >  1:1600. The lymph 
agglutinin titer against suspensions of rat lymph node cells was 1:800. 
All treated animals that survived to adulthood were challenged with Lewis skin homografts 
to determine whether their immunologic reactivity had been affected either by the putative 
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Intravenous inoculations  were always via the anterior facial vein (18). When two inocula- 
tions were required by this route, the veins on opposite sides of the face were employed. 
RESULTS 
Control Data: Effect of Standard Inoculum of Lewis Lymph Node Cells.--To 
evaluate the protective influence of the various agents on runt disease, putative 
therapeutic treatment was withheld from a few members of each fitter of neona- 
tal BN rats inoculated with 20 million Lewis node ceils. As anticipated from the 
previous findings with this strain combination (4), all of a total of 46 BN control 
animals displayed the first clinical signs of the disease within 11-15 days and all 
succumbed within 13-18 days. A similar fate overtook an additional group of nine 
animals which received their Lewis cell inocula via the intraperitoneal  route 
(see Table I, Experiments 1 and 2). 
lnfluence of Administration of Isologous Node Cells from Normal Donors on the 
Development of Runt Disease.--Since  the development of runt disease in the 
context of the present study depends upon the inability of the hosts to reject the 
antigenically  foreign  cells,  through  immunologic  immaturity  and/or  the 
development of tolerance of them, it was assumed that transfusion of BN recip- 
ients with lymphoid cells from normal adult BN rats would furnish them with a 
ready-made, functionally developed, normal immunologic response mechanism, 
i.e., an adoptive protective mechanism. Accordingly, panels of BN rats which 
had received 20 X  106 Lewis node ceils intravenously within 24 hr of birth were 
inoculated with a similar number of BN node cells, either at the same time, or 
after delays of 24, 48, or 72 hr, respectively. 
The results, summarized in Table I, show that whereas virtually complete 
suppression of runt disease was accomplished when the BN ceils were given 
immediately following the Lewis ceils via a different vein (Table I, Experiment 
3), there was no discernible protection if their administration was delayed by 
24 hr or longer (Table I, Experiments 7, 9, 10). Even doubling the number of 
BN cells injected after a delay of only 24 hr failed to impair significantly the 
development or progress of the disease (Table I, Experiment 8). The most strik- 
ing indication of the critical importance of the timing of administration of the 
BN cells was the finding that a delay of as little as 4 hr considerably impaired 
the protection conferred, as evidenced by the 85 % incidence of runt disease and 
the 60 % mortality (Table I, Experiment 5). 
In view of this surprising observation, the influence of prophylactically treat- 
ing neonatal BN hosts intravenously with 20 X  106 isologous node cells from 
normal adult donors 4 hr before intravenous inoculation with 20 million Lewis 
lymphoid cells was investigated. The results (Table I, Experiment 6)  do not 
differ significantly from those reported above, and provide a further indication 
of the critical importance of the time of administration of isologous normal 
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If, instead of inoculating the Lewis node cells and the BN node cells via differ- 
ent veins at approximately the same time, the two inocula were first mixed in 
vitro and then inoculated intravenously, the protective effect was practically as 
good as that obtained when the two cell suspensions were injected separately 
(Table I, Experiment 4). 
These findings show that intimate exposure of the BN cells to the Lewis cells 
before injection is not essential for them to confer protection upon the host. 
However, this certainly does not exclude the possibility that some kind of inti- 
TABLE I 
Influence  of Time and Manner of Administration of a Standard  Inocutum of Node Cells from 
Normal BN Donors into Infant BN Hosts on Their Capacity to Modify the Course of 
Runt Disease Initiated by Injection of 20 Million Lewis Lymph Node Cells 
Route of 
administra- 
tion of 
Exp.  potentially 
harmful 
Lewis  No. 
node cells  X  I0  e 
1  i.v.  None* 
2  i.p.  " 
3  i.v.  20 
4  i.v.  20 
5  i.v.  20 
6  i,v.  20 
7  i.v.  20 
8  i.v.  40 
9  i.v.  20 
10  i.v.  20 
11  i,v.  20 
12  i.p.  20 
Therapeutic BN node 
cells administered 
Time of 
administra- I 
tion after  ~  Route 
injection of 
Lewis cells 
~r  i 
0  !  i.v. 
0  i.v.$ 
+4  i.v. 
-4  i.v. 
+24  !i.v. 
+24  i.v. 
+48  l  i.v. 
+72  i.v. 
0  i.p. 
0  i.v. 
Incidence 
of runt 
disease 
% 
46/46  i00 
9/9  ~100 
1/12  8 
2/13  15 
11/13  85 
9/11  82 
10/10  100 
18/18  100 
7/7  100 
15/15  tO0 
9/14  64 
18/18  100 
Time of 
appearance of 
symptoms 
Range  Median 
days  days 
11-15  12 
12-14  13 
20 
14717 
12-16  13 
12-13  13 
12-13  12 
12-15  13 
13-16  14 
11-14  12 
12-14  12 
12-15  13 
Mortality 
% 
46/46  100 
9/9  il00 
0/12 
1/13  8 
8/18  60 
8/11  73 
10/10  100 
18/18  100 
7/7  100 ' 
15/15  100 
9/14  64 
16/18  89 
Survival time 
Range  Median 
days  days 
13-18  16 
14-20  16 
19 
15-25  16 
15-18  18 
14-16  15 
I~26  17 
18-21  18 
14--17  15 
15-17  15 
15-22  16 
* Controls. 
:~ Mixed with Lewis cells before injection. 
mate relationship may have to be established between the two cell types in vivo 
to invoke a  beneficial immunological response on the part of the BN cells.  If 
this is the case, then HaUer's (21) evidence suggests that the spleen might be the 
organ in which such a confrontation takes place, since this seems to be the tissue 
in which a  large proportion of intravenously injected lymphoid cells rapidly 
become localized in neonatal murine hosts. 
If such  confrontations are important,  then  administration  of  the  two  cell 
populations by physiologically different routes should reduce their incidence, or 
delay their occurrence, and thereby diminish the protective effect of the isolo- 
gous lymph node cells. To investigate this possibility, one panel of neonatal BN 
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immediately by the same number of BN node cells intraperitoneally (Table I, 
Experiment 11). In a second panel of neonatal BN hosts, the routes of inocula- 
tion of the isologous and homologous cell suspensions were reversed,  and the 
BN cells were introduced directly into the blood stream (Table I, Experiment 
12). The results are consistent with the thesis that some kind of prompt in vivo 
cellular confrontation is required to abort the adverse effect of the homologous 
cells, for in both panels there was a high incidence of the disease, and the ma- 
jority of affected animals succumbed. However,  contrary to what might have 
been expected, the incidence of the disease was significantly lower when the BN 
cells  were  introduced  intraperitoneaily, and  the  Lewis  cells intravenously, 
rather than in the converse situation (64 % vs. 100 %: 0.05 >  P  >  0.02). 
TABLE II 
Ability  of Sensitized BN Lymph Node Cells to Modify Course of Runt Disease When Given at 
Various Times after the Inoculation of 20 Million Lewis Lymph Node Cells into Newborn 
BN Rats 
Exp. 
BNnode  ceHs 
administered 
Time of 
No. e  administration 
" 10  after injection 
of Lewis cells 
hr 
20  +3 
20  +4 
2O  +4 
20  ,+5 
20  +5 
20  -[-6 
40  +6 
Incidence of 
¢oute  runt disease 
% 
i.p.  4/13  30 
i.v.  14/14  100 
i.p.  10/10  100 
i.v.  7/8  88 
i.p.  5/5  I00 
i.p.  12/12  100 
Lp.  10/10  100 
Time of 
appearance of 
symptoms 
I 
Range  Median 
days  days 
!12-14  -- 
11-13  12 
]  11-13  12 
11-14  13 
]  13  13 
11-13  12 
11-12  12 
MortaHty 
% 
1/13  8 
13/14  93 
8/I0  80 
4/8  5o 
5/5  100 
12/12  100 
10/10  100 
Survival time 
Range  Median 
days  days 
25 
14-24  13 
13-17  16 
15---16  -- 
15-17  16 
14-17  15 
14--15  15 
Influence  of Administration of Isologous  Node  Cells from  Sensitized  Donors 
on the Development of Runt Disease.--Since  it was anticipated that lymphoid 
ceils from BN donors specifically sensitized against Lewis tissues would exert a 
greater degree  of protection than ceils from unsensitized  donors,  it seemed 
reasonable to delay their administration for at least 3 days after the BN hosts 
had received  their standard neonatal inoculum of 20 million Lewis cells. The 
findings vindicated this decision since only 4 of 13 BN rats which received a 
protective inoculum of 20 X  10  ° BN anti-Lewis lymph node ceils by the intra- 
peritoneal route, 3 days after the intravenous injection of Lewis node cells, 
showed symptoms of the disease and only one of these animals died (Table II, 
Experiment 1). However, when administration of the protective inocnlum was 
delayed until the 4th, 5th, or 6th day, its effectiveness was very significantly 
reduced. At 4 or 5 days (Table II, Experiments 2-5), only 7 of 37 animals were 652  ~gI3"NOTHERAPY  OF  RENT  DISEASE 
saved and none survived when treatment was given on the 6th day (Table II, 
Experiment 6). Indeed, even 40 million BN cells at this time failed to alter the 
course of the disease  (Table II, Experiment 7). Moreover, the route by which 
the sensitized BN cells were given at 4 or 5 days, i.e., whether inoculated intra- 
venously or intraperitoneally,  apparently  made  little,  if any, difference.  The 
influence of administration  of BN cells by the intravenous  route to 6  day old 
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FIG. 1. Illustrating  protective influence of administration of antiserum to BN rats injected 
intravenously with 20 X  106 Lewis lymph node cells on the day of birth. 
The life-span of each subject  is indicated  by a horizontal  line. Thickened  lines indicate 
presence of cutaneous  lesions characteristic  of runt disease. Time of death is indicated  by 
termination  of the lifelines. Arrow heads  along the lifelines indicate  days of injections  of 
standard dose of 0.2 ml of antiserum.  C indicates that animal received serum from normal 
BN donor and is therefore  a control. 
BN hosts was not tested because  of the difficulty of carrying out intravenous 
injections in rats of this age. 
None of the BN hosts receiving  a  neonatal inoculation  of Lewis cells,  and 
surviving as a result of the protective effect of a subsequent inoculation of isolo- 
gous BN node cells, from either normal or sensitized donors, gave any evidence 
of being tolerant of Lewis test skin homografts. 
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results of K/en and his associates (22,  23)  indicated that  isoandsera may be 
more effective in inhibiting GVH reactivity than sensitized lymphoid cells, the 
protective effect of antiserum with the present Lewis and BN rat strains has 
been investigated. 
In all the experiments to be described, the BN subjects received a normally 
lethal intravenous injection of 20 ×  10  e Lewis node cells within 24 hr of birth as 
before. Serum was inoculated by the intraperitoneal route. 
In the first experiment (Fig. 1), each of six 10 day old BN subjects received 
five consecutive daily injections of 0.2 ml of BN anti-Lewis antiserum. On com- 
pletion of this treatment, three of them looked so healthy that no further serum 
was administered. Since the remaining three animals looked less healthy, and 
exhibited some exfoliation of their skins, they received two additional injections 
of the antiserum, on days 15 and 17. All six animals grew up normally. That 
serum from normal, unsensitized BN donors has no protective effect was evi- 
denced by the fact that two littermates of the above animals treated with it died 
of typical runt disease on the 16th day. 
When DA rats (Ag-B*) are immunized with Lewis tissue antigens, the cyto- 
toxic and hemagglutinating antibodies that appear are known to be principally 
directed at antigens determined by the Lewis Ag-B  1 allele.  A  DA anti-Lewis 
isoantiserum should, therefore, confer protection against the ravages of runt 
disease upon infant BN rats injected with Lewis lymphoid cells.  To test this 
prediction (Fig. 1, Experiment 2), eight 10 day old BN rats received daily injec- 
tions of 0.2 ml of DA anti-Lewis serum from days 10 to 18, and a final injection 
on day 20. Although all of these animals had characteristic skin lesions when 
they were 16 days old, and in six the symptoms of runt disease were severe, 
three animals survived to 29 days, and five survived indefinitely, after recover- 
ing slowly from a severe retardation of their growth. Again, a similar regimen 
of treatment of two littermates with normal serum failed to alter the progress of 
the disease, these animals dying on the 16th and 17th days, respectively. 
Finally, to get some idea of the maximal delay in initiation of antiserum ad- 
ministration compatible with a therapeutic influence on runt disease, 10 13 day 
old BN hosts were injected daily with BN anti-Lewis serum, until they either 
succumbed, or attained the age of 22 days. Mter this, no further serum was 
given (Fig. 1, Experiment 3). Although all subjects manifested some tautness or 
lesions of the skin when this treatment was initiated, and six died when they 
were 15-19 days old, four lived to adulthood, after considerable retardation of 
their growth. Compelling evidence that the protective effect was immunologi- 
cally specific was provided by the observation that all 6 BN rats injected daily 
with normal BN serum, from 6 days of age, died on the 16th day. 
Clearly, antiserum at the dosage levels administered is a much more effective 
therapeutic agent than isologous lymphoid cells from normal, or even specifi- 654  IMI~IYNOTHERAP¥  OF  RUNT  DISEASE 
cally sensitized isologous adult donors. Indeed, antiserum can even arrest the 
course of the disease when first given at the time its symptoms have become 
overt. 
None of the survivors of these various experiments gave evidence of being 
tolerant of Lewis tissues when challenged with a Lewis skin homograft. 
Capacity  of Rabbit  Anti-Rat  Lymphocyte  Serum  to Alter the  Course  of Runt 
Disease.--Antiserum  raised  in  one  species  against  lymphoid cells  of  another 
species (heterologous anti-lymphocyte serum, or ALS) has been shown to be a 
relatively harmless, but extremely effective, agent for suppressing the capacity 
TABLE III 
Influence of Injecting  Normal Rabbit Serum or Rabbit Anti-Rat Thymocyte Serum into Infant 
BN Rats Inoculated at Birth with 20 >( 10  ~ Lewis Lymph Node Calls 
Exp.  Type of 
,~rum 
Immune 
Normal 
Immune 
Normal 
Immune 
Normal 
Immune 
Normal 
Immune 
Normal 
Immune 
Normal 
Serum treatment 
Dosage  Time of 
per in-  inoculation 
ocu~tion  after  birth 
ml  days 
0.05  5,7 
0.05  5,7,9,11 
0.05  6,8,10,12 
0.05  6,8,10,12 
0.1  8,10,12,14 
0.1  8,10,12,14 
0.1  10,12,14,16 
0.1  10,12,14,16 
0.1  10,11,12,13 
0.1  10,11,12,13 
0.2  13,14,15 
0.2  13,14,15 
Animals 
developing 
runt  disease 
j)er  No. 
Injected 
5/1t 
6/6 
2/6 
1/1 
9/9 
2/2 
6/6 
3/3 
8/8 
4/4 
5/5 
2/2 
Time of 
appearance of 
symptoms of 
runt disease 
days 
17-19 
12-13 
21-23 
13 
11-18 
11-12 
11-12 
11-12 
11-14 
11-14 
12-13 
I  12-13 
Survival  times of animals, day. 
! 
10-20 21-30 31-40 41-50  >50 
1  3  7 
6 
--  1  5 
1 
3  3  1  2 
2 
6 
3 
4  4 
4 
5 
of members of the lymphoid cell donor species to react against skin homografts 
(24, 25). Furthermore, treatment with ALS can abolish immunological memory 
in animals that have rejected first-set homografts (25), as well as abrogate the 
capacity of lymphoid cells from mice or rats to incite  GVH  reactions  when 
inoculated  into potentially  susceptible homologous hosts  (26-28).  These and 
other findings, such as the ability of ALS treatment of guinea pig hosts to inhibit 
both normal and immune lymphocyte transfer reactions (29)--both expressions 
of  GVH reactivity--constitute a  strong prima facie case  that rabbit anti-rat 
thymocyte serum should afford protection in infant rats otherwise destined to 
develop and succumb to GVH disease. The work now to be described was carried 
out to investigate this possibility. 
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20 X  106 adult Lewis donor lymph node cells as before. Then, commencing 5 or 
6 days later, the animals received two or four daily subcutaneous injections of 
0.05 ml of ALS. To provide controls some littermates, which had also received 
Lewis lymphoid cells at birth,  received decomplemented normal rabbit serum 
instead of ALS. The results (Table III, Experiments  1 and 2)  show that this 
therapy was highly effective since it saved the lives of 12/17  (70 %)  of the sub- 
jects, some of whom had manifested unmistakable signs of runt disease after the 
TABLE IV 
Comparison of Optimal  Protective Effects of Treating  BN Rats Injected  with 20 X  106 Lewis 
Node Cells with (a) Normal Isologous Adult BN Node Cdl*, (b) Node Cells from Adult 
BN Rats Sensitized  against Lewis Tissue A ntigens, (c) Isoimmune Anti-Lewis 
Serum, and (d) tleterologous Rabbit Anti-Rat Thymocyte Serum 
Treatment given to infant BN rats 
Proportion of animals 
which survived 
Therapeutic agent  Time(s) of administration of 
therapeutic agent 
20 X  106 normal BN node cells 
20 X  10  e BN anti-Lewis node 
cells 
BN anti-Lewis serum 0.2 ml 
Rabbit anti-rat  0.05 ml 
thymocyte serum  0.1 ml 
0.1 ml 
--4 hr 
0  ~' 
+4  " 
+24  " 
+3 days 
+4 to 5  " 
+6  " 
Daily +10 to +17 
Daily +13 to +22 
Days  +6,  +8,  +10,  +12 
Days  +8,  +10,  +12,  +14 
Days +10,  +11,  +12,  +13, 
or  +12,  +14,  +16 
% 
3/11  27 
12/12  100 
5/13  38 
0/28  o 
12/13  93 
7/37  19 
0/22  0 
6/6  100 
4/i0  40 
5/6  83 
2/9  22 
0/14  0 
treatment  had  been initiated.  Encouraged  by these findings,  attempts  were 
made to arrest the disease at later stages of its development by commencing the 
therapy at 8, 10, or 13 days after birth and by increasing the dosage of ALS per 
inoculation to 0.1 ml, or even to 0.2 ml. Only when the injections were initiated 
8 days after birth, did a few (22 %) of the subjects make  a full recovery (Table 
III, Experiment 3), though in one group of animals  (Table III, Experiment 5), 
in which initiation of therapy was delayed until the  10th day,  a significant pro- 
longation of life was observed in 50 % of the animals. 
The marked capacity of ALS  to  abort the  development  of runt  disease in 
infant BN rats was unexpected,  since pilot trials had revealed  that  the same 656  rM7~JNOTHERAPY  OF RUNT  DISEASE 
batch of ALS was only marginally effective in prolonging  the survival of BN 
skin grafts on  young adult  (100--120g) Lewis hosts. Treatment of these ani- 
mals with 2 ml of antiserum subcutaneously on days 0,  2,  and  5  only  pro- 
longed the lives of their homografts by 2-3 days. 
Comparison of the present results obtained with ALS (Table III) with those 
obtained with isoantisermn (see Fig. 1 and Table IV) indicates that the latter 
constitutes the more effective protective agent in terms of the age of the hosts at 
which it is still effective. 
DISCUSSION 
The  work  described  above  and  summarized in  Table  IV  indicates  that,  in  rats, 
the capacity of neonatally inoculated adult lymphoid cells  to cause runt or 
homologous disease  in  homologous hosts  can  be  mitigated or  abolished  by inoc- 
ulating  the  latter  with: (a)  lymphoid cells  from  normal or  specifically  sensitized 
isologous  adult donors; (b) isoa~fiserum specifically  directed  against a major 
alien  histocompatibifity  antigen  present  in  the  attacking  cells  and absent in  the 
host;  or  (c)  rabbit  a~ti-rat  lymphocyte serum (ALS).  These  findings  corroborate 
and extend previous observations on the therapy of runt disease  in mice by 
means of isologous  lymphoid cells  or isoantisera  (11-16),  and in rats  by iso- 
antisera (22, 23). 
The timing of the administration of lymphoid cells  from normal isologous 
donors was found to be extremely critical. Only when the harmful and protec- 
tive inocula were mixed before inoculation or, if administered separately, were 
given almost simultaneously via different veins was protection conferred. When 
both inocula were given intravenously, if the protective inoculum either pre- 
ceded or followed the harmful one by as little as 4 hr, the protection obtained 
was greatly reduced. Likewise, if both inocula were injected at the same time, 
but by different routes, the protection afforded was much less than when both 
were injected intravenously. These observations sustain the thesis that a neces- 
sary condition for the conferral of protection by unsensitized isologous lymphoid 
cells is that they must be able to establish a prompt and initimate confrontation 
with the homologous target cells. It is possible that some of the cellular events 
which result from this confrontation in vivo are similar to those which occur 
when lymphocytes from two individuals are mixed and cultured in vitro--i.e., 
mixed lymphocyte interactions (30). If this is the case, then the antigen-sensi- 
tive cells which are presumed to be responsible for these reactions might either 
transform directly into effector cells, or might induce precursor cells present in 
the same population to differentiate into such cells. 
Even when equivalent numbers of lymphoid cells from the homologous and 
isologous adult donors are introduced, and assuming that the proportions of 
specific  antigen-reactive or  immunologically competent cells  present  in  each 
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siderable disadvantage. At all sites in the host the homologous cells are likely to 
undergo intimate exposure to host cellular antigens, so that every cell present 
gets an opportunity to produce a clone of effector cells. However, the chances 
will be much less that all the competent cells in the isologous cell population will 
make the necessary contacts with homologous ceils for stimulation to produce 
effector clones. 
In the light of this reasoning, it is perhaps surprising that the isologous cell 
inocula were able to exert any perceptible protective effect at all when adminis- 
tered independently from the homologous cells. Indeed, their impact might well 
have been much greater had it been possible to introduce them into the rat hosts 
several days before inoculation of the attacking cells, allowing them more time 
to become thoroughly assimilated and functionally efficient. 
The superior protective properties of isologous lymphoid cells from sensitized 
donors--these were still effective when administered 3 or 4 days after the attack- 
ing cells--is probably a function of the high proportion of specific effector cells 
included. In the light of Wilson's (31) in vitro studies, as many as 1% of the 
inoculated isologous cells  may have been capable  of destroying homologous 
donor cells with which they established intimate contact. 
The capacity to abort the development of runt disease in infant rats affords a 
very effective means of differentiating between lymphoid cell populations de- 
rived  from  normal  and  from  specifically  sensitized  isologous  donors, 
respectively. It had previously been shown, in both mice and rats, that one can 
also differentiate between normal lymphoid cells  and those from specifically 
sensitized donors on the basis of their capacity to cause runt disease, or various 
parameters of this syndrome, such as splenomegaly, on inoculation into infant 
homologous hosts (4,  11,  13). However, in the rat, local expressions of GVH 
reactivity, such as the lesions produced at the sites of inoculation of parental 
strain donors cells beneath the renal capsule (32) 1 or in the skins (lymphocyte 
transfer reactions [33, 34]) of genetically appropriate F1 hybrid hosts, afford a 
much less satisfactory means of distinguishing between normal and sensitized 
"attacking" lymphoid cell populations. 
Compared with the protection afforded by cells from even sensitized isologous 
donors, that conferred by repeated injections of isoantiserum was truly remark- 
able because of its capacity to arrest runt disease at a relatively late stage of its 
development. Therapy initiated as late as the 10th or even 13th day was fre- 
quently effective. Presumably the effectiveness of this agent was a function of 
its specific, complement-mediated cytotoxic effect on the homologous lymphoid 
cell population (35).  Obviously, as immunologic effectors, antibody molecules 
should afford a more effective means of eradicating or inactivating a chimeric 
cell population than some kind of cell-bound effector mechanism. 
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That complete recovery can result from late treatment of rats with isoanti- 
serum is important, since it shows that runt disease is not the inevitable sequel 
to irreparable damage inflicted immunologically upon the host during the first 
few days of the GVH reaction (1). It also implies that, in the context of the 
present experiments, some kind of immunological attack must still be taking 
place against the hosts as late as 13 days after inoculation of the Lewis cells. 
Jaffe (36) has recently studied the treatment of homologous disease in chick 
embryos, using inhibition of splenomegaly as a  parameter of the therapeutic 
effect of inocula of normal or sensitized leukocytes (present in blood), or anti- 
serum from isologous adult donors. Normal isologous ceils only conferred protec- 
tion if administered 3 days before the putatively harmful homologous lymphoid 
cell inoculum, whereas cells or antiserum from sensitized donors both afforded 
significant degrees of protection when administered at the same time as the 
attacking cells. ]affe considers that pretreatment with the unsensitized cells was 
necessary to enable them to become established and furnish the embryo With a 
partially functional immunologic apparatus. 
Although it has been well-established that pretreatment of an adult donor 
With  heterologous anti-lymphocyte serum  (26-28)  will impair or abolish the 
capacity of its lymphoid cells to cause runt disease on inoculation into geneti- 
cally appropriate hosts, we are not aware of any reports of ALS treatment of 
infant hosts destined to develop the disease. In the present study, it was found 
that repeated injections of rabbit anti-rat thymus serum saved the lives of rats 
inoculated with it, as late as the 6th or even the 8th day after receiving Lewis 
lymphoid cells. However, it was less effective than isoantiserum. 
The finding that some BN rats recovered from runt disease after receiving 
initial inoculation of ALS at 6--8 days suggests that in this experimental situa- 
tion the action of this agent may be directed against the efferent rather than the 
afferent limb of the immunological reflex. 
It is important to point out that any analysis of the mechanism(s) underlying 
the protective action of the various agents described must take into account the 
demonstration by McBride et al. (37) that GVH reactions in chick embryos can 
induce a precocious maturation of immunologic competence on the part of host 
cells. 
Although all the survivors of the various experiments described were chal- 
lenged with skin grafts from Lewis donors to determine whether their early 
exposure  to Lewis lymphoid ceils  had affected their subsequent  capacity to 
react against Lewis tissue antigens, none was found to manifest the slightest 
degree of tolerance. This observation is not surprising in view of the fact that 
with the rat strain combination employed lymphoid cells  (unlike bone marrow 
cells) are very ineffective in inducing tolerance of skin homografts. The findings 
do not exclude the possibility that some of the animals tested may have been 
lymphoid cell chimeras (4). WILLYS K.  SILVERS AND R.  E.  BILLINGHA~r  659 
SUMMARY 
Using rats of the Lewis and BN (Ag-B locus incompatible) isogenic strains, a 
comparative study has been made of the capacity to prevent or mitigate the 
development of runt disease with: (a) lymph node cell suspensions from normal 
adult BN rats, (b) node cells, or (c) serum from donors sensitized against Lewis 
tissue  antigens,  or  (d)  heterologous anti-lymphocyte serum  (ALS)  raised in 
rabbits against rat thymocytes. 
Following a standard intravenous or intraperitoneal inoculation of 20 X  106 
Lewis node cells into neonatal BN hosts, there are cutaneous manifestations of 
runt disease within 11-15 days and death invariably takes place within 20 days. 
However, complete protection is afforded by administration of a similar number 
of normal BN node cells via a  different vein, or admixed with the otherwise 
harmful Lewis node cells. However, timing of the administration was  crucially 
important--precedence or delay by as little as 4 hr resulted in  a great impair- 
ment of protection. When  the inoculations of the  two  cell  suspensions  were 
separated by 24 hr, no protection was afforded. These and other observations 
suggested that a necessary condition for protection of the hosts by unseusitized 
isologous cells requires that they establish a prompt and intimate confrontation 
with the homologous target cells. 
At the same dosage level, suspensions of node cells from sensitized isologous 
donors were much more effective therapeutically, saving the lives of 92 %  of 
treated subjects when administered after a delay of 3 days, and of 19 % when the 
delay was 4 or 5 days. 
Of the various immunotherapeutic agents studied, daily injections of 0.2 ml 
of isoantiserum gave the best results, and could totally reverse the course of the 
disease even when initiated at age 10-13 days and subjects already presented 
symptoms. ALS, although inferior to isoantiserum at the dosage levels tested, 
proved to be superior to sensitized isologous cells as a protective agent, since the 
initiation of daily injections after delays of 6 or 8 days were still effective. 
The observations that delayed treatments of infant rats with isoantisera  or 
ALS resulted in complete recoveries sustain the thesis that the lesions responsi- 
ble for the fatal outcome of runt diseases are not inflicted at a very early stage. 
The efficacy  of both isoantisera and ALS as a means of inhibiting the progression 
of homologous disease also suggests that they may have therapeutic value in 
situations where this condition is encountered. 
The authors are deeply indebted to Dr. Darcy B. Wilson and Dr. Charles Shaffer for 
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